Clinical Trials in Poland / NCT07787429
Recruiting
Phase 2
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
NCT07787429 · tracked via the Priya Life Science Poland tracker
Condition(s) studied
Osteosarcoma
Investigational drug(s) / intervention(s)
Mifamurtide: Mifamurtide is a synthetic analog of muramyl dipeptide, which works by stimulating the immune system to destroy cancer cells. The exact mechanism of this activation in humans is unknown. The MEPACT product is a liposomal form of mifamurtide specifically formulated to reach macrophages in vivo after administration by intravenous infusion.
Sorafenib: Sorafenib is a small-molecule, broad-spectrum tyrosine kinase inhibitor that slows cancer cell growth and reduces angiogenesis. Sorafenib is unique among new kinase inhibitors as it simultaneously inhibits the Raf, Mek, and Erk kinase pathways.
Study summary
Prospective, open, interventional, randomized, non-commercial trial
Eligibility
Inclusion Criteria:
Part I:
1. Age ≥ 5 to ≤ 30 years at the time of qualification.
2. Histopathologically confirmed osteosarcoma based on previous diagnostic tests.
3. Provision of written, informed consent to participate in the study, including treatment with mifamurtide and sorafenib, in accordance with current legal regulations, prior to the initiation of any study procedures.
Part II:
1. Participants of the Part I classified as high-risk.
2. Expected survival of at least 12 weeks from the time of signing informed consent.
3. Patient deemed capable of receiving systemic treatment.
4. Patient able to swallow tablets.
5. Disease in complete remission or stable disease per WHO criteria before randomization.
6. Major surgery performed ≥ 2 weeks and radiotherapy ≥ 4 weeks before inclusion in the mifamurtide group.
7. Recovery from adverse effects of prior surgery and/or radiotherapy.
8. Signed informed consent to participate in the study (including mifamurtide and sorafenib treatment) in accordance with applicable legal regulations.
9. Agreement to use effective contraception throughout the study period and for at least one year after discontinuing treatment for patients of reproductive age.
Exclusion Criteria:
1. Failure to meet any of the inclusion criteria.
2. Previous treatment with mifamurtide.
3. Hypersensitivity to the investigational drug or any of its components (including mifamurtide and sorafenib).
4. Concurrent treatment with drugs that may interact with mifamurtide, sorafenib, or other cytostatics.
5. Persistent toxicity from prior therapy that precludes treatment with mifamurtide or sorafenib.
6. Significant cardiac conduction abnormalities, including a known family history of long QT syndrome or a corrected QT interval (QTc) \> 480 ms.
7. Symptoms of congestive heart failure or a left ventricular ejection fraction \< 50%.
8. Need or probable need for corticosteroids at doses \> 10 mg of prednisone (or equivalent) daily or other immunosuppressive drugs.
9. Uncontrolled blood pressure.
10. Arterial or venous thromboembolic events, such as stroke (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months before the first administration of the investigational drug.
11. Active hepatitis B or C or chronic hepatitis B or C requiring antiviral therapy.
12. Any bleeding or hemorrhagic event ≥ CTCAE v5 grade 3 within 4 weeks before the first administration of the investigational drug.
13. Diagnosis of other malignancies prior to study entry.
14. Pregnancy planning, current pregnancy, or breastfeeding.
15. Other acute or persistent disorders, behaviors, or abnormal laboratory results that may increase the risk associated with participation in this clinical study or receiving the investigational drug, may impact study results interpretation, or, in the investigator's opinion, disqualify the patient from study participation
Primary outcome measure(s)
- Event-Free Survival (EFS) — 10,3 months
EFS (Event-Free Survival) - the time from randomization to the first event, i.e., death, disease progression, or disease relapse, whichever occurs first. Assessment will be conducted from the date of randomization until the date of the event or the date of the last available assessment
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Mother and Child Institute | Warsaw | Mazovian | Recruiting |
More Anna Raciborska trials in Poland
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Active, not recruiting
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Active, not recruiting
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07787429 on ClinicalTrials.gov ↗ ← All trials in Poland